European Union
MDR / IVDR pathways, EMA-related pharmaceutical work, clinical evidence, QMS and notified-body readiness.
MARKETS / JURISDICTION-AWARE DELIVERY
Coverage that is useful because it is specific.
A market is not a logo on a map. It is a set of pathway, evidence, quality, clinical, technical and lifecycle requirements that must be made visible.
GLOBAL COVERAGE MATRIX
Start with the markets that matter to the programme.
Coverage is presented as a working matrix: what applies, where evidence can travel, what needs local execution and what should be verified next.
United Kingdom
MHRA-facing pathway analysis, UKCA context, evidence and technical documentation planning.
United States
FDA pathway framing across IND / NDA / BLA, 510(k), De Novo, PMA and pre-submission preparation.
China
NMPA, CDE, CMDE and China market-entry planning, evidence acceptability, clinical strategy and registration support.
Hainan Lecheng
Special-use pathways, healthcare institution coordination, RWD / RWE and innovation landing support.
Middle East / GCC
Market-entry framing, local partner interfaces, product documentation and readiness planning by country.
HOW TO READ THE MATRIX
Every market view should answer five questions.
01What is the product?
Product type, intended purpose, risk and maturity.
02What is the pathway?
Which route is plausible and what must be verified?
03What evidence travels?
What can be reused and what needs local generation?
04Who must execute?
Which work belongs to Hope Focus and which to a specialist?
05What is next?
The next decision, work package or readiness review.